REFERENCES
601.
Naguib M, Selim M, Bakhamees HS, et al: Enzymatic
versus pharmacologic antagonism of profound mivacurium-induced neuromuscular blockade.
Anesthesiology 84:1051–1059, 1996.
602.
Szenohradszky J, Lau M, Brown R, et al: The effect
of neostigmine on twitch tension and muscle relaxant concentration during infusion
of mivacurium or vecuronium. Anesthesiology 83:83–87, 1995.
603.
Hart PS, Wright PM, Brown R, et al: Edrophonium
increases mivacurium concentrations during constant mivacurium infusion, and large
doses minimally antagonize paralysis. Anesthesiology 82:912–918, 1995.
604.
Bevan DR, Kahwaji R, Ansermino JM, et al: Residual
block after mivacurium with or without edrophonium reversal in adults and children.
Anesthesiology 84:362–367, 1996.
605.
Mirakhur RK: Spontaneous recovery or evoked reversal
of neuromuscular block. Acta Anaesthesiol Scand Suppl 106:62–65, 1995.
606.
Naguib M, Daoud W, el-Gammal M, et al: Enzymatic
antagonism of mivacurium-induced neuromuscular blockade by human plasma cholinesterase.
Anesthesiology 83:694–701, 1995.
607.
Naguib M, Samarkandi AH, Bakhamees HS, et al:
Edrophonium and human plasma cholinesterase combination for antagonism of mivacurium-induced
neuromuscular block. Br J Anaesth 77:424–426, 1996.
608.
Ostergaard D, Jensen FS, Viby-Mogensen J: Reversal
of intense mivacurium block with human plasma cholinesterase in patients with atypical
plasma cholinesterase. Anesthesiology 82:1295–1298, 1995.
609.
Delisle S, Bevan DR: Impaired neostigmine antagonism
of pancuronium during enflurane anaesthesia in man. Br J Anaesth 54:441–445,
1982.
610.
Morita T, Tsukagoshi H, Sugaya T, et al: Inadequate
antagonism of vecuronium-induced neuromuscular block by neostigmine during sevoflurane
or isoflurane anesthesia. Anesth Analg 80:1175–1180, 1995.
611.
Morita T, Kurosaki D, Tsukagoshi H, et al: Sevoflurane
and isoflurane impair edrophonium reversal of vecuronium-induced neuromuscular block.
Can J Anaesth 43:799–805, 1996.
612.
Morita T, Kurosaki D, Tsukagoshi H, et al: Factors
affecting neostigmine reversal of vecuronium block during sevoflurane anaesthesia.
Anaesthesia 52:538–543, 1997.
613.
Reid JE, Breslin DS, Mirakhur RK, et al: Neostigmine
antagonism of rocuronium block during anesthesia with sevoflurane, isoflurane or
propofol. Can J Anaesth 48:351–355, 2001.
614.
Kumar N, Mirakhur RK, Symington MJ, et al: Potency
and time course of action of rocuronium during desflurane and isoflurane anaesthesia.
Br J Anaesth 77:488–491, 1996.
615.
Lowry DW, Mirakhur RK, McCarthy GJ, et al: Neuromuscular
effects of rocuronium during sevoflurane, isoflurane, and intravenous anesthesia.
Anesth Analg 87:936–940, 1998.
616.
Astley BA, Katz RL, Payne JP: Electrical and
mechanical responses after neuromuscular blockade with vecuronium, and subsequent
antagonism with neostigmine or edrophonium. Br J Anaesth 59:983–988, 1987.
617.
Goldhill DR, Wainwright AP, Stuart CS, et al:
Neostigmine after spontaneous recovery from neuromuscular blockade. Effect on depth
of blockade monitored with train-of-four and tetanic stimuli. Anaesthesia 44:293–299,
1989.
618.
Miller RD, Roderick LL: Acid-base balance and
neostigmine antagonism of pancuronium neuromuscular blockade. Br J Anaesth 50:317–324,
1978.
619.
Biro K: Effects of respiratory and metabolic
alkalosis and acidosis on pipecuronium neuromuscular block. Eur J Pharmacol 154:329–333,
1988.
620.
Miller RD, Van Nyhuis LS, Eger EI 2nd, et al:
The effect of acid-base balance on neostigmine antagonism of d-tubocurarine-induced
neuromuscular blockade. Anesthesiology 42:377–383, 1975.
621.
Feldman S: Effect of changes in electrolytes,
hydration, and pH upon the reactions to muscle relaxants. Br J Anaesth 35:546–551,
1963.
622.
Cohen EN: The choice and mode of administration
of relaxants. 5. Patients with altered sensitivity. Clin Anesth 2:75–93,
1966.
623.
Cunningham JN Jr, Carter NW, Rector FC Jr, et
al: Resting transmembrane potential difference of skeletal muscle in normal subjects
and severely ill patients. J Clin Invest 50:49–59, 1971.
624.
Miller RD, Roderick LL: Diuretic-induced hypokalaemia,
pancuronium neuromuscular blockade and its antagonism by neostigmine. Br J Anaesth
50:541–544, 1978.
625.
Jones RM, Cashman JN, Casson WR, et al: Verapamil
potentiation of neuromuscular blockade: Failure of reversal with neostigmine but
prompt reversal with edrophonium. Anesth Analg 64:1021–1025, 1985.
626.
Wali FA: Interaction of verapamil with gallamine
and pancuronium and reversal of combined neuromuscular blockade with neostigmine
and edrophonium. Eur J Anaesthesiol 3:385–393, 1986.
627.
Pavlin DJ: T4/T1 does not predict recovery from
vecuronium in the presence of gentamicin [abstract]. Anesthesiology 79:A918, 1993.
628.
Salem MG, Richardson JC, Meadows GA, et al: Comparison
between glycopyrrolate and atropine in a mixture with neostigmine for reversal of
neuromuscular blockade. Studies in patients following open heart surgery. Br J
Anaesth 57:184–187, 1985.
629.
Fisher DM, Cronnelly R, Sharma M, et al: Clinical
pharmacology of edrophonium in infants and children. Anesthesiology 61:428–433,
1984.
630.
Fogdall RP, Miller RD: Antagonism of d-tubocurarine-
and pancuronium-induced neuromuscular blockades by pyridostigmine in man. Anesthesiology
39:504–509, 1973.
631.
Dodd P, Day SJ, Goldhill DR, et al: Glycopyrronium
requirements for antagonism of the muscarinic side effects of edrophonium. Br J
Anaesth 62:77–81, 1989.
632.
Triantafillou AN, Tsueda K, Berg J, et al: Refractory
bradycardia after reversal of muscle relaxant in a diabetic with vagal neuropathy.
Anesth Analg 65:1237–1241, 1986.
633.
Naguib M, Gomaa M, Absood GH: Atropine-edrophonium
mixture: A dose-response study. Anesth Analg 67:650–655, 1988.
634.
Parlow JL, van Vlymen JM, Odell MJ: The duration
of impairment of autonomic control after anticholinergic drug administration in humans.
Anesth Analg 84:155–159, 1997.
635.
van Vlymen JM, Parlow JL: The effects of reversal
of neuromuscular blockade on autonomic control in the perioperative period. Anesth
Analg 84:148–154, 1997.
636.
Rabey PG, Smith G: Anaesthetic factors contributing
to postoperative nausea and vomiting. Br J Anaesth 69(7 Suppl 1):40S–45S,
1992.
637.
Ding Y, Fredman B, White PF: Use of mivacurium
during laparoscopic surgery: Effect of reversal drugs on postoperative recovery.
Anesth Analg 78:450–454, 1994.
638.
Boeke AJ, de Lange JJ, van Druenen B, et al:
Effect of antagonizing residual neuromuscular block by neostigmine and atropine on
postoperative vomiting. Br J Anaesth 72:654–656, 1994.
639.
Hovorka J, Korttila K, Nelskyla K, et al: Reversal
of neuromuscular blockade with neostigmine has no effect on the incidence or severity
of postoperative nausea and vomiting. Anesth Analg 85:1359–1361, 1997.
640.
Tramer MR, Fuchs-Buder T: Omitting antagonism
of neuromuscular block: Effect on postoperative nausea and vomiting and risk of
residual paralysis. A systematic review. Br J Anaesth 82:379–386, 1999.
641.
Cronnelly R, Stanski DR, Miller RD, et al: Renal
function and the pharmacokinetics of neostigmine in anesthetized man. Anesthesiology
51:222–226, 1979.
642.
Cronnelly R, Stanski DR, Miller RD, et al: Pyridostigmine
kinetics with and without renal function. Clin Pharmacol Ther 28:78–81, 1980.
643.
Morris RB, Cronnelly R, Miller RD, et al: Pharmacokinetics
of edrophonium in anephric and renal transplant patients. Br J Anaesth 53:1311–1314,
1981.
644.
Morris RB, Cronnelly R, Miller RD, et al: Pharmacokinetics
of edrophonium and neostigmine when antagonizing d-tubocurarine
neuromuscular blockade in man. Anesthesiology 54:399–401, 1981.
645.
Kopman AF: Edrophonium antagonism of pancuronium-induced
neuromuscular blockade in man: A reappraisal. Anesthesiology 51:139–142,
1979.
646.
Bevan DR: Reversal of pancuronium with edrophonium.
Anaesthesia 34:614–619, 1979.
647.
Barber HE, Calvey TN, Muir KT: The relationship
between the pharmacokinetics, cholinesterase inhibition and facilitation of twitch
tension of the quaternary ammonium anticholinesterase drugs, neostigmine, pyridostigmine,
edrophonium and 3-hydroxyphenyltrimethylammonium. Br J Pharmacol 66:525–530,
1979.
648.
Verotta D, Kitts J, Rodriguez R, et al: Reversal
of neuromuscular blockade in humans by neostigmine and edrophonium: A mathematical
model. J Pharmacokinet Biopharm 19:713–729, 1991.
649.
Bom A, Bradley M, Cameron K, et al: A novel concept
of reversing neuromuscular block: Chemical encapsulation of rocuronium bromide by
a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl 41:266–270, 2002.
650.
Adam JM, Bennett DJ, Bom A, et al: Cyclodextrin-derived
host molecules as reversal agents for the neuromuscular blocker rocuronium bromide:
Synthesis and structure-activity relationships. J Med Chem 45:1806–1816,
2002.
651.
Tarver GJ, Grove SJ, Buchanan K, et al: 2-O-substituted
cyclodextrins as reversal agents for the neuromuscular blocker rocuronium bromide.
Bioorg Med Chem 10:1819–1827, 2002.
652.
Cameron KS, Clark JK, Cooper A, et al: Modified
gammacy-clodextrins and their rocuronium complexes. Org Lett 4:3403–3406,
2002.
653.
Epemolu O, Bom A, Hope F, Mason R: Reversal of
neuromuscular blockade and simultaneous increase in plasma rocuronium concentration
after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology
99:632–637, 2003.
654.
Bom A, Mason R, McIndewar I: Org 25060 causes
rapid reversal of rocuronium-induced neuromuscular block, independent of acid-base
status [abstract]. Anesthesiology 97:A1009, 2002.
655.
Gihsenbergh F, Ramael S, De Bruyn S, et al: Preliminary
assessment of Org 25969 as a reversal agent for rocuronium in healthy male volunteers
[abstract]. Anesthesiology 97:A1008, 2002.
656.
Kelly SS: The effect of age on neuromuscular
transmission. J Physiol 274:51–62, 1978.
657.
Goudsouzian NG: Maturation of neuromuscular transmission
in the infant. Br J Anaesth 52:205–214, 1980.
658.
Genever EE: Suxamethonium-induced cardiac arrest
in unsuspected pseudohypertrophic muscular dystrophy. Case report. Br J Anaesth
43:984–986, 1971.
659.
Henderson WA: Succinylcholine-induced cardiac
arrest in unsuspected Duchenne muscular dystrophy. Can Anaesth Soc J 31:444–446,
1984.
660.
Bennett EJ, Ignacio A, Patel K, et al: Tubocurarine
and the neonate. Br J Anaesth 48:687–689, 1976.
661.
Goudsouzian NG, Ryan JF, Savarese JJ: The neuromuscular
effects of pancuronium in infants and children. Anesthesiology 41:95–98, 1974.
662.
Goudsouzian NG, Donlon JV, Savarese JJ, et al:
Re-evaluation of dosage and duration of action of d-tubocurarine
in the pediatric age group. Anesthesiology 43:416–425, 1975.
663.
Bennett EJ, Ramamurthy S, Dalal FY, et al: Pancuronium
and the neonate. Br J Anaesth 47:75–78, 1975.
664.
Fisher DM, O'Keeffe C, Stanski DR, et al: Pharmacokinetics
and pharmacodynamics of d-tubocurarine in infants,
children, and adults. Anesthesiology 57:203–208, 1982.
665.
Fisher DM, Castagnoli K, Miller RD: Vecuronium
kinetics and dynamics in anesthetized infants and children. Clin Pharmacol Ther
37:402–406, 1985.
666.
Fisher DM, Miller RD: Neuromuscular effects of
vecuronium (ORG NC45) in infants and children during N2
O, halothane anesthesia.
Anesthesiology 58:519–523, 1983.
667.
Meretoja OA, Gebert R: Postoperative neuromuscular
block following atracurium or alcuronium in children. Can J Anaesth 37:743–746,
1990.
668.
Baxter MR, Bevan JC, Samuel J, et al: Postoperative
neuromuscular function in pediatric day-care patients. Anesth Analg 72:504–508,
1991.
669.
Meretoja OA, Wirtavuori K, Neuvonen PJ: Age-dependence
of the dose-response curve of vecuronium in pediatric patients during balanced anesthesia.
Anesth Analg 67:21–26, 1988.
670.
Meretoja OA: Is vecuronium a long-acting neuromuscular
blocking agent in neonates and infants? Br J Anaesth 62:184–187, 1989.
671.
Brandom BW, Woelfel SK, Cook DR, et al: Clinical
pharmacology of atracurium in infants. Anesth Analg 63:309–312, 1984.
672.
Goudsouzian NG, Liu LM, Cote CJ, et al: Safety
and efficacy of atracurium in adolescents and children anesthetized with halothane.
Anesthesiology 59:459–462, 1983.
673.
Meretoja OA, Kalli I: Spontaneous recovery of
neuromuscular function after atracurium in pediatric patients. Anesth Analg 65:1042–1046,
1986.
674.
Meretoja OA, Taivainen T, Wirtavuori K: Cisatracurium
during halothane and balanced anaesthesia in children. Paediatr Anaesth 6:373–378,
1996.
675.
de Ruiter J, Crawford MW: Dose-response relationship
and infusion requirement of cisatracurium besylate in infants and children during
nitrous oxide-narcotic anesthesia. Anesthesiology 94:790–792, 2001.
676.
Scheiber G, Ribeiro FC, Marichal A, et al: Intubating
conditions and onset of action after rocuronium, vecuronium, and atracurium in young
children. Anesth Analg 83:320–324, 1996.
677.
Taivainen T, Meretoja OA, Erkola O, et al: Rocuronium
in infants, children and adults during balanced anaesthesia. Paediatr Anaesth 6:271–275,
1996.
678.
Reynolds LM, Lau M, Brown R, et al: Intramuscular
rocuronium in infants and children. Dose-ranging and tracheal intubating conditions.
Anesthesiology 85:231–239, 1996.
679.
Kaplan RF, Uejima T, Lobel G, et al: Intramuscular
rocuronium in infants and children: A multicenter study to evaluate tracheal intubating
conditions, onset, and duration of action. Anesthesiology 91:633–638, 1999.
680.
Sarner JB, Brandom BW, Woelfel SK, et al: Clinical
pharmacology of mivacurium chloride (BW B1090U) in children during nitrous oxide-halothane
and nitrous oxide-narcotic anesthesia. Anesth Analg 68:116–121, 1989.
681.
Goudsouzian NG, Alifimoff JK, Eberly C, et al:
Neuromuscular and cardiovascular effects of mivacurium in children. Anesthesiology
70:237–242, 1989.
682.
Goudsouzian NG, Martyn JJ, Liu LM, et al: Safety
and efficacy of vecuronium in adolescents and children. Anesth Analg 62:1083–1088,
1983.
683.
Hart PS, McCarthy GJ, Brown R, et al: The effect
of plasma cholinesterase activity on mivacurium infusion rates. Anesth Analg 80:760–763,
1995.
684.
Markakis DA, Hart PS, Lau M, et al: Does age
or pseudocholinesterase activity predict mivacurium infusion rate in children? Anesth
Analg 82:39–43, 1996.
685.
Fisher DM, Cronnelly R, Miller RD, et al: The
neuromuscular pharmacology of neostigmine in infants and children. Anesthesiology
59:220–225, 1983.
686.
Bevan JC, Tousignant C, Stephenson C, et al:
Dose responses for neostigmine and edrophonium as antagonists of mivacurium in adults
and children. Anesthesiology 84:354–361, 1996.
687.
Frolkis VV, Martynenko OA, Zamostyan VP: Aging
of the neuromuscular apparatus. Gerontology 22:244–279, 1976.
688.
Matteo RS, Backus WW, McDaniel DD, et al: Pharmacokinetics
and pharmacodynamics of d-tubocurarine and metocurine
in the elderly. Anesth Analg 64:23–29, 1985.
689.
McLeod K, Hull CJ, Watson MJ: Effects of ageing
on the pharmacokinetics of pancuronium. Br J Anaesth 51:435–438, 1979.
690.
Duvaldestin P, Saada J, Berger JL, et al: Pharmacokinetics,
pharmacodynamics, and dose-response relationships of pancuronium in control and elderly
subjects. Anesthesiology 56:36–40, 1982.
691.
d'Hollander A, Massaux F, Nevelsteen M, et al:
Age-dependent dose-response relationship of ORG NC 45 in anaesthetized patients.
Br J Anaesth 54:653–657, 1982.
692.
Dresner DL, Basta SJ, Ali HH, et al: Pharmacokinetics
and pharmacodynamics of doxacurium in young and elderly patients during isoflurane
anesthesia. Anesth Analg 71:498–502, 1990.
693.
Ornstein E, Matteo RS, Schwartz AE, et al: Pharmacokinetics
and pharmacodynamics of pipecuronium bromide (Arduan) in elderly surgical patients.
Anesth Analg 74:841–844, 1992.
694.
d'Hollander AA, Luyckx C, Barvais L, et al: Clinical
evaluation of atracurium besylate requirement for a stable muscle relaxation during
surgery: Lack of age-related effects. Anesthesiology 59:237–240, 1983.
695.
Maddineni VR, Mirakhur RK, McCoy EP: Plasma cholinesterase
activity in elderly and young adults. Br J Anaesth 72:497, 1994.
696.
Maddineni VR, Mirakhur RK, McCoy EP, et al: Neuromuscular
and haemodynamic effects of mivacurium in elderly and young adult patients. Br J
Anaesth 73:608–612, 1994.
697.
Goudsouzian N, Chakravorti S, Denman W, et al:
Prolonged mivacurium infusion in young and elderly adults. Can J Anaesth 44:955–962,
1997.
698.
Tsueda K, Warren JE, McCafferty LA, et al: Pancuronium
bromide requirement during anesthesia for the morbidly obese. Anesthesiology 48:438–439,
1978.
699.
Feingold A: Pancuronium requirements of the morbidly
obese. Anesthesiology 50:269–270, 1979.
700.
Soderberg M, Thomson D, White T: Respiration,
circulation and anesthetic management in obesity. Investigation before and after
jejunoileal bypass. Acta Anaesthesiol Scand 21:55–61, 1977.
701.
Schmith VD, Fiedler-Kelly J, Abou-Donia M, et
al: Population pharmacodynamics of doxacurium. Clin Pharmacol Ther 52:528–536,
1992.
702.
Weinstein JA, Matteo RS, Ornstein E, et al: Pharmacodynamics
of vecuronium and atracurium in the obese surgical patient. Anesth Analg 67:1149–1153,
1988.
703.
Puhringer FK, Khuenl-Brady KS, Mitterschiffthaler
G: Rocuronium bromide: Time-course of action in underweight, normal weight, overweight
and obese patients. Eur J Anaesthesiol Suppl 11:107–110, 1995.
704.
Beemer GH, Bjorksten AR, Crankshaw DP: Effect
of body build on the clearance of atracurium: Implication for drug dosing. Anesth
Analg 76:1296–1303, 1993.
705.
Vandenbrom RH, Wierda JM, Agoston S: Pharmacokinetics
and neuromuscular blocking effects of atracurium besylate and two of its metabolites
in patients with normal and impaired renal function. Clin Pharmacokinet 19:230–240,
1990.
706.
Fahey MR, Morris RB, Miller RD, et al: Pharmacokinetics
of Org NC45 (Norcuron) in patients with and without renal failure. Br J Anaesth
53:1049–1053, 1981.
707.
Bencini AF, Scaf AH, Sohn YJ, et al: Disposition
and urinary excretion of vecuronium bromide in anesthetized patients with normal
renal function or renal failure. Anesth Analg 65:245–251, 1986.
708.
Meistelman C, Lienhart A, Leveque C, et al: Pharmacology
of vecuronium in patients with end-stage renal failure. Eur J Anaesthesiol 3:153–158,
1986.
709.
Lynam DP, Cronnelly R, Castagnoli KP, et al:
The pharmacodynamics and pharmacokinetics of vecuronium in patients anesthetized
with isoflurane with normal renal function or with renal failure. Anesthesiology
69:227–231, 1988.
710.
Fairley HB: Prolonged intercostal paralysis due
to a relaxant. BMJ 76:1296, 1950.
711.
Orko R, Heino A, Rosenberg PH, et al: Dose-response
of tubocurarine in patients with and without renal failure. Acta Anaesthesiol Scand
28:452–456, 1984.
712.
Ward S, Neill EA: Pharmacokinetics of atracurium
in acute hepatic failure (with acute renal failure). Br J Anaesth 55:1169–1172,
1983.
713.
Bevan DR, Donati F, Gyasi H, et al: Vecuronium
in renal failure. Can Anaesth Soc J 31:491–496, 1984.
714.
Khuenl-Brady KS, Pomaroli A, Puhringer F, et al:
The use of rocuronium (ORG 9426) in patients with chronic renal failure. Anaesthesia
48:873–875, 1993.
715.
Blobner M, Jelen-Esselborn S, Schneider G, et
al: Effect of renal function on neuromuscular block induced by continuous infusion
of mivacurium. Br J Anaesth 74:452–454, 1995.
716.
Ramzan MI, Somogyi AA, Walker JS, et al: Clinical
pharmacokinetics of the non-depolarising muscle relaxants. Clin Pharmacokinet 6:25–60,
1981.
717.
Cashman JN, Luke JJ, Jones RM: Neuromuscular
block with doxacurium (BW A938U) in patients with normal or absent renal function.
Br J Anaesth 64:186–192, 1990.
718.
Mongin-Long D, Chabrol B, Baude C, et al: Atracurium
in patients with renal failure. Clinical trial of a new neuromuscular blocker.
Br J Anaesth 58(Suppl 1):44S–48S, 1986.
719.
Hunter JM, Jones RS, Utting JE: Use of atracurium
in patients with no renal function. Br J Anaesth 54:1251–1258, 1982.
720.
Parker CJ, Jones JE, Hunter JM: Disposition of
infusions of atracurium and its metabolite, laudanosine, in patients in renal and
respiratory failure in an ITU. Br J Anaesth 61:531–540, 1988.
721.
Eastwood NB, Boyd AH, Parker CJ, et al: Pharmacokinetics
of 1R-cis 1'R-cis
atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic
renal failure. Br J Anaesth 75:431–435, 1995.
722.
Segredo V, Matthay MA, Sharma ML, et al: Prolonged
neuromuscular blockade after long-term administration of vecuronium in two critically
ill patients. Anesthesiology 72:566–570, 1990.
723.
Hunter JM, Jones RS, Utting JE: Comparison of
vecuronium, atracurium and tubocurarine in normal patients and in patients with no
renal function. Br J Anaesth 56:941–951, 1984.
724.
Lepage JY, Malinge M, Cozian A, et al: Vecuronium
and atracurium in patients with end-stage renal failure. A comparative study. Br
J Anaesth 59:1004–1010, 1987.
725.
Cooper RA, Mirakhur RK, Wierda JM, et al: Pharmacokinetics
of rocuronium bromide in patients with and without renal failure. Eur J Anaesthesiol
Suppl 11:43–44, 1995.
726.
Szenohradszky J, Caldwell JE, Sharma ML, et al:
Interaction of rocuronium (ORG 9426) and phenytoin in a patient undergoing cadaver
renal transplantation: A possible pharmacokinetic mechanism? Anesthesiology 80:1167–1170,
1994.
727.
Phillips BJ, Hunter JM: Use of mivacurium chloride
by constant infusion in the anephric patient. Br J Anaesth 68:492–498, 1992.
728.
Ryan DW: Preoperative serum cholinesterase concentration
in chronic renal failure. Clinical experience of suxamethonium in 81 patients undergoing
renal transplant. Br J Anaesth 49:945–949, 1977.
729.
Ostergaard D, Jensen FS, Jensen E, et al: Influence
of plasma cholinesterase activity on recovery from mivacurium-induced neuromuscular
blockade in phenotypically normal patients. Acta Anaesthesiol Scand 36:702–706,
1992.
730.
El-Hakim M, Baraka A: d-Tubocurarine
in liver disease. Kar-El-Aini 4:99, 1963.
731.
Lebrault C, Duvaldestin P, Henzel D, et al: Pharmacokinetics
and pharmacodynamics of vecuronium in patients with cholestasis. Br J Anaesth 58:983–987,
1986.
732.
Servin FS, Lavaut E, Kleef U, Desmonts JM: Repeated
doses of rocuronium bromide administered to cirrhotic and control patients receiving
isoflurane. A clinical and pharmacokinetic study. Anesthesiology 84:1092–1100,
1996.
733.
Westra P, Vermeer GA, de Lange AR, et al: Hepatic
and renal disposition of pancuronium and gallamine in patients with extrahepatic
cholestasis. Br J Anaesth 53:331–338, 1981.
734.
Ramzan IM, Shanks CA, Triggs EJ: Pharmacokinetics
and pharmacodynamics of gallamine triethiodide in patients with total biliary obstruction.
Anesth Analg 60:289–296, 1981.
735.
Lawhead RG, Matsumi M, Peters KR, et al: Plasma
laudanosine levels in patients given atracurium during liver transplantation. Anesth
Analg 76:569–573, 1993.
736.
Nana A, Cardan E, Leitersdorfer T: Pancuronium
bromide. Its use in asthmatics and patients with liver disease. Anaesthesia 27:154–158,
1972.
737.
Gyasi HK, Naguib M: Atracurium and severe hepatic
disease: A case report. Can Anaesth Soc J 32:161–164, 1985.
738.
Bell CF, Hunter JM, Jones RS, Utting JE: Use
of atracurium and vecuronium in patients with oesophageal varices. Br J Anaesth
57:160–168, 1985.
739.
Hunter JM, Parker CJ, Bell CF, et al: The use
of different doses of vecuronium in patients with liver dysfunction. Br J Anaesth
57:758–764, 1985.
740.
Kim C, Martyn J, Fuke N: Burn injury to trunk
of rat causes denervation-like responses in the gastrocnemius muscle. J Appl Physiol
65:1745–1751, 1988.
741.
Kim C, Fuke N, Martyn JA: Burn injury to rat
increases nicotinic acetylcholine receptors in the diaphragm. Anesthesiology 68:401–406,
1988.
742.
Ward JM, Rosen KM, Martyn JA: Acetylcholine receptor
subunit mRNA changes in burns are different from those seen after denervation: The
1993 Lindberg Award. J Burn Care Rehabil 14:595–601, 1993.
743.
Nosek MT, Martyn JA: Na+
channel and
acetylcholine receptor changes in muscle at sites distant from burns do not simulate
denervation. J Appl Physiol 82:1333–1339, 1997.
744.
Ibebunjo C, Martyn JA: Thermal injury induces
greater resistance to d-tubocurarine in local rather
than in distant muscles in the rat. Anesth Analg 91:1243–1249, 2000.
745.
Ibebunjo C, Martyn J: Disparate dysfunction of
skeletal muscles located near and distant from burn site in the rat. Muscle Nerve
24:1283–1294, 2001.
746.
Martyn JA, Szyfelbein SK, Ali HH, et al: Increased
d-tubocurarine requirement following major thermal
injury. Anesthesiology 52:352–355, 1980.
747.
Edwards JP, Hatton PA, Little RA, et al: Increased
quantal release of acetylcholine at the neuromuscular junction following scald injury
in the rat. Muscle Nerve 22:1660–1666, 1999.
748.
Tomera JF, Lilford K, Martyn JA: Diaphragm acetylcholinesterase
multimeric forms in mice in response to burn trauma. J Burn Care Rehabil 14:406–419,
1993.
749.
Cronan T, Hammond J, Ward CG: The value of isokinetic
exercise and testing in burn rehabilitation and determination of back-to-work status.
J Burn Care Rehabil 11:224–227, 1990.
750.
St-Pierre DM, Choiniere M, Forget R, et al: Muscle
strength in individuals with healed burns. Arch Phys Med Rehabil 79:155–161,
1998.
